RxDoctor Payments Data

Phuong-Khanh Farley, MD

Interventional Cardiology · Corsicana, TXNPI 1386888444

Payments from drug & device makers

$1,254in general payments, 2019–2025

Across 62 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$245
  • Biotronik Inc.$181
  • Scpharmaceuticals Inc.$106
  • E.r. Squibb & Sons, L.L.C.$89
  • Actelion Pharmaceuticals US, Inc.$76
  • Philips North America LLC$71
  • plus $487 from 14 others

What the payments were for

  • Food & beverage$1,22698%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,254 in reported general payments places this provider in the 5th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$166,162
Medicare patients
559
Services billed
1,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$137,152
XareltoRivaroxaban50$53,525
Atorvastatin Calcium396$2,838
Metoprolol Succinate162$1,527
ClopidogrelClopidogrel Bisulfate141$1,518
Ezetimibe94$1,450
Potassium Chloride102$1,442
Carvedilol198$1,441
FenofibrateFenofibrate,micronized42$1,407
Losartan Potassium207$1,407
Ranolazine ErRanolazine14$1,260
Metoprolol Tartrate186$1,174
Amlodipine Besylate201$1,092
Amiodarone Hcl52$1,053
Furosemide206$1,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$137,152132 claims
Johnson & JohnsonXarelto$54$53,52550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Corsicana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →